AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇿🇦
Empagliflozin & Linagliptin in South Africa
2 products registered with SAHPRA — 2 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| GLYXAMBI 10/5 mg | 55/21.2/0030 | Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale | active | 18 Oct 2027 |
| GLYXAMBI 25/5 mg | 55/21.2/0031 | Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale | active | 18 Oct 2027 |
Empagliflozin & Linagliptin — SAHPRA Registration Details
SAHPRA (South Africa) has 2 registered products containing Empagliflozin & Linagliptin, of which 2 are currently active. Data is sourced directly from the official SAHPRA drug register and refreshed daily.
Track Empagliflozin & Linagliptin registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.